Literature DB >> 24126221

Current controversies in radiotherapy for nasopharyngeal carcinoma (NPC).

Michael K M Kam1, Frank C S Wong2, Dora L W Kwong3, Henry C K Sze3, Anne W M Lee4.   

Abstract

Radiotherapy has a good track record in the treatment of NPC, yet the late toxicity profile and local failure rate for locally advanced disease remain a concern. Modern RT techniques incorporating IMRT and IGRT have widened our potential in treating NPC more effectively, and shall be regarded as the standard of care. Out of the various dose fractionation regimens in IMRT, 70 Gy in 35 fractions or the mini-SIB proves to be safe in combination with chemotherapy, but any further attempt of dose escalation must be tried out with extreme caution to avoid severe toxicities. CT-MRI image fusion improves the accuracy of GTV delineation, whereas the role of PET-CT has yet to be verified. RTOG definition of the CTV provides a reasonable template for the inclusion of sites at risk of microscopic involvement, and fine tuning has to be made in the future based on careful analysis of the pattern of local failure with long term follow-up. Toxicity reduction via radiation volume or dose reduction is tempting, but once again it has to be tested under scrutiny. Retrospective data have emerged that suggest a benefit of using adaptive IMRT replanning in NPC, however the optimal timing or frequency of replanning is still unclear. Future prospective studies are thus required to evaluate the cost-effectiveness of adaptive RT and streamline the workflow logistics before it can be widely accepted in routine practice.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Altered fractionation; Dose escalation; Image-guidance radiotherapy; Intensity-modulated radiotherapy; Nasopharyngeal carcinoma

Mesh:

Year:  2013        PMID: 24126221     DOI: 10.1016/j.oraloncology.2013.09.013

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  9 in total

1.  Nasopharyngeal carcinoma in a low incidence European area : A prospective observational analysis from the Head and Neck Study Group of the Italian Society of Radiation Oncology (AIRO).

Authors:  S Tonoli; D Alterio; O Caspiani; A Bacigalupo; F Bunkheila; M Cianciulli; A Merlotti; A Podhradska; M Rampino; D Cante; L Bruschieri; R Gatta; S M Magrini
Journal:  Strahlenther Onkol       Date:  2016-10-19       Impact factor: 3.621

2.  DW-MRI-Guided Dose Escalation Improves Local Control of Locally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy.

Authors:  Guohui Xu; Jinyi Lang; Yecai Huang; Mei Feng; Xuegang Yang; Jie Zhou; Lu Li; Ke Xu
Journal:  Cancer Manag Res       Date:  2020-05-06       Impact factor: 3.989

3.  The Prognosis Value of PSPC1 Expression in Nasopharyngeal Cancer.

Authors:  Huocong He; Lurong Zhang; Keyu Lin; Zhengrong Huang; Yan Zhou; Shaojun Lin; Ying Su; Jianru Pan
Journal:  Cancer Manag Res       Date:  2021-04-14       Impact factor: 3.989

Review 4.  LncRNA H19: A novel oncogene in multiple cancers.

Authors:  Jun Yang; Manlong Qi; Xiang Fei; Xia Wang; Kefeng Wang
Journal:  Int J Biol Sci       Date:  2021-07-25       Impact factor: 6.580

5.  Use dose bricks concept to implement nasopharyngeal carcinoma treatment planning.

Authors:  Jia-Ming Wu; Tsan-Jung Yu; Shyh-An Yeh; Pei-Ju Chao; Chih-Jou Huang; Tsair-Fwu Lee
Journal:  Biomed Res Int       Date:  2014-05-21       Impact factor: 3.411

6.  Pretreatment Dynamic Contrast-Enhanced MRI Improves Prediction of Early Distant Metastases in Patients With Nasopharyngeal Carcinoma.

Authors:  Shy-Chyi Chin; Chien-Yu Lin; Bing-Shen Huang; Ngan-Ming Tsang; Kang-Hsing Fan; Yi-Kang Ku; Cheng-Lung Hsu; Sheng-Chieh Chan; Shiang-Fu Huang; Cheng-He Li; Hsiao-Jung Tseng; Chun-Ta Liao; Ho-Ling Liu; Kyunghyun Sung
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

7.  Concurrent chemoradiotherapy for T3-4 and N0-1 nasopharyngeal cancer: Asian multicenter trial of the Forum for Nuclear Cooperation in Asia.

Authors:  Tatsuya Ohno; Masaru Wakatsuki; Dang Huy Quoc Thinh; Ngo Thanh Tung; Dyah Erawati; Nana Supriana; C R Beena Devi; Shingo Kato; Kullathorn Thephamongkhol; Yaowalak Chansilpa; Miriam Joy C Calaguas; Xu Xiaoting; Cao Jianping; Parvin Akhter Banu; Chul-Koo Cho; Kumiko Karasawa; Takashi Nakano; Hirohiko Tsujii
Journal:  J Radiat Res       Date:  2015-08-08       Impact factor: 2.724

8.  Dose escalation via brachytherapy boost for nasopharyngeal carcinoma in the era of intensity-modulated radiation therapy and combined chemotherapy.

Authors:  Hsing-Lung Chao; Shao-Cheng Liu; Chih-Cheng Tsao; Kuen-Tze Lin; Steve P Lee; Cheng-Hsiang Lo; Wen-Yen Huang; Ming-Yueh Liu; Yee-Min Jen; Chun-Shu Lin
Journal:  J Radiat Res       Date:  2017-09-01       Impact factor: 2.724

9.  Circular RNA CDR1as sponges miR-7-5p to enhance E2F3 stability and promote the growth of nasopharyngeal carcinoma.

Authors:  Qiong Zhong; Juncong Huang; Jiawang Wei; Renrui Wu
Journal:  Cancer Cell Int       Date:  2019-10-01       Impact factor: 5.722

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.